The new Pfizer/BioNTech vaccine has met requirements of protection, first-class and effectiveness. A second ‘bivalent’ Covid vaccine has been accepted by the United Kingdom’s Medicines and Healthcare merchandise Regulatory Agency (MHRA).
But what’s the new vaccine, who can be eligible to receive it and when will it be available?
A 2nd ‘bivalent’ Covid jab has been accepted to be used in the UK for those elderly 12 and over.
The MHRA confirmed on Saturday (3 September) that Pfizer/BioNTech’s vaccine had met its requirements of safety, quality and effectiveness and have been accepted for the UK autumn booster programme. The vaccine objectives the unique variant of coronavirus and the Omicron variant that emerged at the end of 2021.
The new jab follows the approval of a similar booster from Moderna in August. ‘Bivalent’ vaccines had been developed by global manufacturers since the emergence and dominance of the Omicron variant.
Thee vaccines incorporate distinctive antigens (substances that induce an immune response) based on distinctive Covid-19 lines or variants. The original mRNA vaccines incorporate one antigen (monovalent), based at the original ‘wild-type’ strain. The decision to approve this 2nd bivalent vaccine was based on data from a scientific trial, which confirmed that a booster dose with the bivalent Pfizer/BioNTech vaccine triggers a strong immune response against Omicron and the original strain.
Safety tracking of side-effects located all through the trial showed they were similar to the ones visible for the original Pfizer/BioNTech booster dose, and had been typically moderate and self-resolving, without a new severe safety concerns identified. The new bivalent Covid vaccine can be used in the autumn booster programme.
Dr June Raine, the MHRA leader executive, stated: “I am pleased to announce that we’ve a second approved vaccine for the United Kingdom autumn booster programme. The scientific trial of the Pfizer/BioNTech bivalent vaccine confirmed a strong immune reaction against the Omicron BA.1 variant as well as the original strain. “Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants.”
When will it be available?
Pfizer’s UK country president, Susan Rienow, stated the company has been production the new vaccine at risk – ahead of approval being granted – and doses “can be shipped right away to be used in the autumn booster programme to help defend humans in the UK this winter season”.
Professor Wei Shen Lim, the chair of Covid-19 immunization at the Joint Committee on Vaccination and Immunization (JCVI), stated it is “very encouraging” that more vaccines continue to become available. Adding that iciness became commonly the time of best chance from respiration infections, the professor endorsed all people who became eligible to have their booster vaccine this fall while it became offered.
He stated: “This is our best defense towards becoming severely ill from Covid-19.”Those eligible for a Covid autumn booster jab can be contacted by the NHS, with the rollout starting from September onward